Press releases

Healthcare

Treatment for AMD: the Autorité fines 3 laboratories for abusive practices

Published on September 09, 2020

DMLA

The Autorité de la concurrence has imposed fines worth a total of €444 million on three pharmaceutical companies, Novartis, Roche and Genentech, for abusive practices designed to sustain the sales of Lucentis for AMD treatment to the detriment of Avastin (a competitive medicinal product that is 30 times cheaper).

Sanction dans le secteur de l'ophtalmologie